Allogeneic stem cell transplantation (SCT) in Ph+ CML: still a therapeutic option? | springermedizin.at

Springer Medizin Österreich

nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.04.2010 | Short Review

Allogeneic stem cell transplantation (SCT) in Ph+ CML: still a therapeutic option?

verfasst von: Otto Krieger, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Anzeige

Vorheriger Artikel Iron chelation therapy in myelodysplastic syndromes: evidence-based rationale and comparison of guidelines

Nächster Artikel Haemolytic anaemia triggered by antitumoural “biological agents” and immunotherapies with monoclonal antibodies: short review of the literature

Titel: Allogeneic stem cell transplantation (SCT) in Ph+ CML: still a therapeutic option?
verfasst von: Otto Krieger, MD
Publikationsdatum: 01.04.2010
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 1/2010
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-010-0177-8

Weitere Artikel der Ausgabe 1/2010

Biomarkers of angiogenesis and their role in clinical oncology

Short Review

Fibroblast growth factor receptors (FGFR) as possible therapeutic targets in human non-small cell lung cancer

Short Review

Changing paradigms in clinical trials

Editorial

Austrian consensus recommendations for the treatment of patients with multiple myeloma

Consensus Report

Haemolytic anaemia triggered by antitumoural “biological agents” and immunotherapies with monoclonal antibodies: short review of the literature

Special Report

Iron chelation therapy in myelodysplastic syndromes: evidence-based rationale and comparison of guidelines

Short Review